Released Mar 3, 2016, after the close
10-K filed Mar 3, 2016, 63 days after period end · 0001564590-16-013981
Q4 2015 · 10-K
Revenue$1.08M$1.08M no prior Q4 2014 on file+4.9% vs Q3 2015
Net Income-$7.45M-$7.45M N/M vs Q4 2014N/M vs Q3 2015
EPS Diluted-$0.26-$0.26 N/M vs Q4 2014N/M vs Q3 2015
Operating Incomederived-$6,912,000N/M
Operating Cash Flowderived-$6,970,000N/M
Free Cash Flowderived-$7,148,000N/M
Margins · derived
Operating margin-642.4%
Net margin-692.0%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2015 | Q4 2014 | Q4 2013 | Q4 2012 |
|---|---|---|---|---|
| Revenue | $1.08M | — | $0.00 | $643.00K |
| Net Income | -$7.45M | -$6.23M | -$5.74M | -$4.16M |
| EPS Diluted | -$0.26 | -$0.30 | -$0.29 | -$3.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR